BGI Co-Win
Overview
BGI Co-Win, founded in 2016, is the corporate venture capital arm of BGI Group, based in Shenzhen, China . The firm invests in medical technology, gene technology, and biomedical companies . It targets early-stage industries, including biotechnology, healthcare IT, pharmaceuticals, and medical supplies .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Lingbo Biotechnology (Hangzhou) Co., Ltd. | Nov 2023 | Series A | Co-investor |
| Hangzhou Bioer Technology Co., Ltd. | Jul 2020 | Series A | Co-investor |
| EdiGene | Aug 2018 | VC Round | - |
| uBriGene Biosciences | Sep 2022 | Series C | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is BGI Co-Win based?
BGI Co-Win is headquartered in Shenzhen, Guangdong, China.
When was BGI Co-Win founded?
BGI Co-Win was founded in 2016.
How many portfolio companies does BGI Co-Win have?
BGI Co-Win has 4 portfolio companies in Caplight's dataset.
What are some companies in BGI Co-Win's portfolio?
Portfolio companies visible on Caplight include Lingbo Biotechnology (Hangzhou) Co., Ltd., Hangzhou Bioer Technology Co., Ltd., EdiGene, uBriGene Biosciences.
What was BGI Co-Win's most recent investment shown here?
BGI Co-Win's most recent investment in this portfolio sample was in Lingbo Biotechnology (Hangzhou) Co., Ltd. in 2023.
What sectors does BGI Co-Win focus on?
BGI Co-Win focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does BGI Co-Win focus on?
Stage focus information for BGI Co-Win is not publicly available.
What is BGI Co-Win's AUM?
BGI Co-Win's assets under management are estimated between $100.0M and $250.0M.